神経内分泌腫瘍治療の世界市場

神経内分泌腫瘍治療の世界市場は2030年までに44億米ドルに達する見込み

2024年に33億米ドルと推定される神経内分泌腫瘍治療の世界市場は、分析期間2024-2030年にCAGR 4.6%で成長し、2030年には44億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるソマトスタチン類似体は、CAGR 3.7%を記録し、分析期間終了時には15億米ドルに達すると予測されます。化学療法分野の成長率は、分析期間中CAGR 4.7%と推定されます。

米国市場は9億840万米ドルと推定、中国はCAGR7.2％で成長予測

米国の神経内分泌腫瘍治療市場は、2024年に9億840万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを7.2%として、2030年までに8億5,020万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.3%と4.6%と予測されています。欧州では、ドイツがCAGR 2.9%で成長すると予測されています。

世界の神経内分泌腫瘍治療市場- 主要動向と促進要因まとめ

神経内分泌腫瘍がより専門的な治療アプローチを必要とするのはなぜか？

神経内分泌腫瘍（NET）は、神経内分泌細胞から発生する悪性腫瘍の一群で、消化管、肺、膵臓に最も多く見られます。歴史的にはまれで成長が遅いと考えられてきたが、診断技術の向上と臨床的意識の高まりにより、NETの罹患率は上昇しています。NETは多くの場合、緩徐であるにもかかわらず、その挙動が多様であること、ホルモン分泌の可能性があること、発見が後期であることなどから、特有の課題があります。そのため、NETの臨床管理は、腫瘍のコントロールと症状管理を組み合わせた、より個別化された集学的戦略へとシフトしています。

NETは、高分化で機能しない腫瘍から、非常に攻撃的でホルモン活性の高い新生物まで様々であるため、治療には細胞減量とホルモン制御の微妙なバランスが必要です。従来の細胞毒性化学療法は多くのNET亜型において有効性に限界があり、標的療法、ペプチド受容体放射性核種療法（PRRT）、生物学的療法への移行を促しています。これらの進化する戦略は、単に無増悪生存期間を延長するだけでなく、特にカルチノイド症候群のような症状を引き起こす機能性NET患者のQOLを改善することを目的としています。

標的治療とPRRTは現代の治療パラダイムをどのように形成しているか？

標的療法は、従来の化学療法と比較して、より正確で忍容性の高い選択肢を提供し、進行性または転移性NETの治療の要となっています。エベロリムス（mTOR阻害剤）やスニチニブ（チロシンキナーゼ阻害剤）などの薬剤は、膵臓および非膵臓NETにおいて無増悪生存期間の延長に有効であることが実証されています。これらの治療は、腫瘍増殖と血管新生に関与する分子経路を阻害するため、腫瘍生物学に基づいたよりテーラーメードの治療が可能となります。

ペプチド受容体放射性核種治療（PRRT）、特にLutetium 177 DOTATATEなどの放射性同位元素標識ソマトスタチン類似体を用いた治療は、ソマトスタチン受容体陽性NET患者に対する非常に有効な選択肢として浮上してきました。PRRTは腫瘍細胞に標的を絞って放射線を照射するため、周辺組織へのダメージを最小限に抑え、持続的な病勢コントロールが可能です。PRRTの成功は、より新しい放射性核種薬剤や併用レジメンの研究を促進しました。さらに、オクトレオチドやランレオチドなどのソマトスタチン類似体は、機能性腫瘍患者の症状コントロールと腫瘍の安定化に不可欠です。これらの進歩は、より少ない副作用で患者の転帰を改善する、生物学的に誘導された非侵襲的治療への幅広い動向を強調するものです。

どのような診断およびモニタリング戦略が治療の精度を高めているか？

画像診断とバイオマーカー同定の進歩は、神経内分泌腫瘍のより正確な病期分類とモニタリングを可能にしています。ガリウム-68 DOTATATE PET/CTのような機能的画像技術は、ソマトスタチン受容体の発現を評価するための標準となっており、これは診断を助けるだけでなくPRRTの適格性を決定します。このような精密画像診断は、従来のスキャンよりも解像度と感度が高く、早期介入とより的を絞った治療計画を容易にします。

さらに、クロモグラニンA（CgA）やニューロン特異的エノラーゼ（NSE）などの循環バイオマーカーは、ゲノムプロファイリングや循環腫瘍DNA（ctDNA）評価によって補完されつつあります。これらのツールは、腫瘍の悪性度、増殖指数（Ki-67）、潜在的な耐性メカニズムに関する洞察を提供し、臨床医が治療法を動的に適応させることを可能にします。治療レジメンが複雑化するにつれ、画像診断や分子診断による継続的なモニタリングによって、治療が疾患の進行や腫瘍生物学の進展に沿ったものとなることが保証されます。このような精密さ主導のアプローチは、NETsの管理を再構築し、より効果的な長期コントロールへの扉を開くものです。

神経内分泌腫瘍治療市場の成長を促進する要因は？

神経内分泌腫瘍治療市場の成長は、臨床革新、疾患認知度の向上、標的治療経路の広範な導入に関連するいくつかの連動した要因によって牽引されています。主要な推進力は、より洗練された画像診断技術や診断アルゴリズムの改良に支えられた、NETの発生率と検出率の増加です。臨床医がNETの特異な病態、特に早期患者の病態を理解するようになり、診断率は上昇し、治療可能な患者層が拡大しています。

三次医療病院、がん専門センター、大学医療機関などでのエンドユースの拡大が、PRRT、標的生物学的製剤、画像誘導介入などの先進治療の幅広い採用を支えています。高コストの治療に対する償還支援や有利な規制当局の承認も、患者の新規治療へのアクセスを促進しています。さらに、免疫療法、放射性核種併用療法、新しいソマトスタチン受容体アナログに焦点を当てた臨床試験への投資が増加しており、市場の革新的パイプラインを強化しています。

患者支援団体による支援や、がん啓発キャンペーンにNETを取り上げる動きが活発化していることも、この疾患に対する社会的・臨床的認知度を高めています。標的治療、放射性医薬品、ホルモン抑制、サーベイランスを組み合わせたマルチモーダルな治療戦略が主流となるにつれ、専門的で精度の高い治療薬に対する需要は着実に拡大する見通しです。このような情勢が、神経内分泌腫瘍治療の持続的な発展と商業的拡大を後押ししています。

セグメント

薬剤クラス（ソマトスタチン類似体、化学療法、標的療法、免疫療法、その他薬剤クラス別）、適応症（消化管NET、肺NET、膵NET、その他適応症）、販売チャネル（病院薬局、オンライン薬局、小売薬局）

調査対象企業の例（注目の41社）

• Advanced Accelerator Applications
• AVEO Oncology
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Camurus AB
• Delcath Systems
• Eli Lilly and Company
• Exelixis, Inc.
• Hutchison MediPharma
• Ipsen
• ITM Isotopen Technologien Munchen AG
• Jubilant Pharmova Limited
• Lantheus Holdings, Inc.
• Novartis AG
• Orano Med
• Pfizer Inc.
• Progenics Pharmaceuticals
• Radiomedix, Inc.
• RayzeBio, Inc.
• Sanofi

AI統合

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Neuroendocrine Tumor Treatment Market to Reach US$4.4 Billion by 2030

The global market for Neuroendocrine Tumor Treatment estimated at US$3.3 Billion in the year 2024, is expected to reach US$4.4 Billion by 2030, growing at a CAGR of 4.6% over the analysis period 2024-2030. Somatostatin Analogs, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$1.5 Billion by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 4.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$908.4 Million While China is Forecast to Grow at 7.2% CAGR

The Neuroendocrine Tumor Treatment market in the U.S. is estimated at US$908.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$850.2 Million by the year 2030 trailing a CAGR of 7.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.3% and 4.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Global Neuroendocrine Tumor Treatment Market - Key Trends & Drivers Summarized

Why Are Neuroendocrine Tumors Requiring More Specialized Therapeutic Approaches?

Neuroendocrine tumors (NETs) are a heterogeneous group of malignancies that originate from neuroendocrine cells, most commonly found in the gastrointestinal tract, lungs, and pancreas. While historically considered rare and slow-growing, NETs have seen a rise in incidence due to improved diagnostic techniques and heightened clinical awareness. Despite their often indolent nature, NETs present unique challenges due to their variable behavior, potential for hormone secretion, and late-stage detection. The clinical management of NETs has therefore shifted toward more individualized, multidisciplinary strategies that combine tumor control with symptom management.

Because NETs can range from well-differentiated, non-functioning tumors to highly aggressive and hormonally active neoplasms, treatment requires a delicate balance between cytoreduction and hormonal control. Traditional cytotoxic chemotherapy has limited effectiveness in many NET subtypes, prompting a move toward targeted therapies, peptide receptor radionuclide therapy (PRRT), and biotherapy. These evolving strategies aim not just to extend progression-free survival but also to improve quality of life, especially for patients with functional NETs causing symptoms like carcinoid syndrome.

How Are Targeted Therapies and PRRT Shaping Modern Treatment Paradigms?

Targeted therapies have become a cornerstone in the treatment of advanced or metastatic NETs, offering more precise and tolerable options compared to traditional chemotherapy. Agents such as everolimus (an mTOR inhibitor) and sunitinib (a tyrosine kinase inhibitor) have demonstrated efficacy in prolonging progression-free survival in pancreatic and non-pancreatic NETs. These therapies interfere with molecular pathways involved in tumor proliferation and angiogenesis, allowing for more tailored treatment based on tumor biology.

Peptide receptor radionuclide therapy (PRRT), particularly with radiolabeled somatostatin analogs like Lutetium-177-DOTATATE, has emerged as a highly effective option for patients with somatostatin receptor-positive NETs. PRRT delivers targeted radiation to tumor cells, minimizing damage to surrounding tissues and providing durable disease control. Its success has driven further research into newer radionuclide agents and combination regimens. Additionally, somatostatin analogs such as octreotide and lanreotide remain vital for symptom control and tumor stabilization in patients with functional tumors. These advancements underscore a broader trend toward biologically guided, non-invasive therapies that improve patient outcomes with fewer adverse effects.

Which Diagnostic and Monitoring Strategies Are Enhancing Treatment Precision?

Advances in diagnostic imaging and biomarker identification are enabling more accurate staging and monitoring of neuroendocrine tumors. Functional imaging techniques such as Gallium-68 DOTATATE PET/CT have become standard for assessing somatostatin receptor expression, which not only aids diagnosis but also determines eligibility for PRRT. This form of precision imaging provides better resolution and sensitivity than traditional scans, facilitating earlier intervention and more targeted treatment planning.

Additionally, circulating biomarkers such as chromogranin A (CgA) and neuron-specific enolase (NSE) are being complemented by genomic profiling and circulating tumor DNA (ctDNA) assessments. These tools provide insights into tumor grade, proliferation index (Ki-67), and potential resistance mechanisms, enabling clinicians to adapt therapy dynamically. As treatment regimens become more complex, ongoing monitoring through imaging and molecular diagnostics ensures that therapy remains aligned with disease progression and evolving tumor biology. This precision-driven approach is reshaping the management of NETs and opening the door to more effective long-term control.

What Factors Are Driving Growth in the Neuroendocrine Tumor Treatment Market?

The growth in the neuroendocrine tumor treatment market is driven by several interlinked factors related to clinical innovation, rising disease awareness, and broader adoption of targeted care pathways. A key driver is the increasing incidence and detection of NETs, supported by more sophisticated imaging techniques and improved diagnostic algorithms. As clinicians become more attuned to the unique presentation of NETs, especially in early-stage patients, diagnosis rates are climbing, expanding the treatable patient pool.

End-use expansion across tertiary care hospitals, cancer specialty centers, and academic medical institutions is supporting the wider adoption of advanced therapies like PRRT, targeted biologics, and image-guided interventions. Reimbursement support for high-cost treatments and favorable regulatory approvals are also facilitating patient access to novel therapies. Additionally, growing investment in clinical trials focused on immunotherapy, radionuclide combinations, and new somatostatin receptor analogs is enhancing the market’s innovation pipeline.

Support from patient advocacy groups and increased inclusion of NETs in cancer awareness campaigns are driving both public and clinical recognition of the disease. As multi-modal treatment strategies become the norm-incorporating targeted therapy, radiopharmaceuticals, hormone suppression, and surveillance-the demand for specialized, high-precision therapeutics is poised to grow steadily. Collectively, these trends are fostering sustained advancement and commercial expansion within the neuroendocrine tumor treatment landscape.

SCOPE OF STUDY:

The report analyzes the Neuroendocrine Tumor Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy, Other Drug Classes); Indication (Gastrointestinal NET, Lung NET, Pancreatic NET, Other Indications); Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Advanced Accelerator Applications
• AVEO Oncology
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Camurus AB
• Delcath Systems
• Eli Lilly and Company
• Exelixis, Inc.
• Hutchison MediPharma
• Ipsen
• ITM Isotopen Technologien Munchen AG
• Jubilant Pharmova Limited
• Lantheus Holdings, Inc.
• Novartis AG
• Orano Med
• Pfizer Inc.
• Progenics Pharmaceuticals
• Radiomedix, Inc.
• RayzeBio, Inc.
• Sanofi

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Neuroendocrine Tumor Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Incidence of Neuroendocrine Tumors Drives Demand for Advanced and Targeted Therapies
  • OEM Innovation in Somatostatin Analogs Enhances First-Line Treatment Options for NET Patients
  • Growth in Peptide Receptor Radionuclide Therapy (PRRT) Supports Expansion of Theranostic-Based NET Treatment
  • Push for Molecular Diagnostics and Biomarker Profiling Enables Personalized Medicine in NET Management
  • Increased Use of Next-Generation Sequencing (NGS) Aids in Subtyping and Target Identification for NET Therapies
  • Expansion of Targeted Therapy Pipelines Fuels Development of mTOR, VEGF, and Tyrosine Kinase Inhibitors
  • Rising Clinical Trial Activity for Novel Radiopharmaceuticals Strengthens Long-Term Treatment Pipeline
  • OEM Development of Extended-Release and Depot Formulations Enhances Patient Compliance
  • High Unmet Need in Advanced-Stage and Metastatic NETs Drives Interest in Combination Regimens
  • Surge in Patient Awareness and Specialist Referral Networks Promotes Earlier Diagnosis and Intervention
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Neuroendocrine Tumor Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Neuroendocrine Tumor Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Neuroendocrine Tumor Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Somatostatin Analogs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Somatostatin Analogs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Somatostatin Analogs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Gastrointestinal NET by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Gastrointestinal NET by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Gastrointestinal NET by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Lung NET by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Lung NET by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Lung NET by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Pancreatic NET by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Pancreatic NET by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Pancreatic NET by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Neuroendocrine Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Neuroendocrine Tumor Treatment by Drug Class - Percentage Breakdown of Value Sales for Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Neuroendocrine Tumor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Neuroendocrine Tumor Treatment by Indication - Percentage Breakdown of Value Sales for Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Neuroendocrine Tumor Treatment by Drug Class - Percentage Breakdown of Value Sales for Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Neuroendocrine Tumor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Neuroendocrine Tumor Treatment by Indication - Percentage Breakdown of Value Sales for Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications for the Years 2015, 2025 & 2030
• JAPAN
  • Neuroendocrine Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Neuroendocrine Tumor Treatment by Drug Class - Percentage Breakdown of Value Sales for Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Neuroendocrine Tumor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Neuroendocrine Tumor Treatment by Indication - Percentage Breakdown of Value Sales for Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications for the Years 2015, 2025 & 2030
• CHINA
  • Neuroendocrine Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 68: China Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Neuroendocrine Tumor Treatment by Drug Class - Percentage Breakdown of Value Sales for Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Neuroendocrine Tumor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Neuroendocrine Tumor Treatment by Indication - Percentage Breakdown of Value Sales for Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications for the Years 2015, 2025 & 2030
• EUROPE
  • Neuroendocrine Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Neuroendocrine Tumor Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Neuroendocrine Tumor Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Neuroendocrine Tumor Treatment by Drug Class - Percentage Breakdown of Value Sales for Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Neuroendocrine Tumor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Neuroendocrine Tumor Treatment by Indication - Percentage Breakdown of Value Sales for Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications for the Years 2015, 2025 & 2030
• FRANCE
  • Neuroendocrine Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 89: France Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Neuroendocrine Tumor Treatment by Drug Class - Percentage Breakdown of Value Sales for Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Neuroendocrine Tumor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: France 15-Year Perspective for Neuroendocrine Tumor Treatment by Indication - Percentage Breakdown of Value Sales for Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications for the Years 2015, 2025 & 2030
• GERMANY
  • Neuroendocrine Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Neuroendocrine Tumor Treatment by Drug Class - Percentage Breakdown of Value Sales for Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Neuroendocrine Tumor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Germany 15-Year Perspective for Neuroendocrine Tumor Treatment by Indication - Percentage Breakdown of Value Sales for Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Neuroendocrine Tumor Treatment by Drug Class - Percentage Breakdown of Value Sales for Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Neuroendocrine Tumor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Italy 15-Year Perspective for Neuroendocrine Tumor Treatment by Indication - Percentage Breakdown of Value Sales for Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Neuroendocrine Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 116: UK Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Neuroendocrine Tumor Treatment by Drug Class - Percentage Breakdown of Value Sales for Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Neuroendocrine Tumor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 122: UK Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: UK 15-Year Perspective for Neuroendocrine Tumor Treatment by Indication - Percentage Breakdown of Value Sales for Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Neuroendocrine Tumor Treatment by Drug Class - Percentage Breakdown of Value Sales for Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Neuroendocrine Tumor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Spain 15-Year Perspective for Neuroendocrine Tumor Treatment by Indication - Percentage Breakdown of Value Sales for Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Neuroendocrine Tumor Treatment by Drug Class - Percentage Breakdown of Value Sales for Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Neuroendocrine Tumor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Russia 15-Year Perspective for Neuroendocrine Tumor Treatment by Indication - Percentage Breakdown of Value Sales for Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Neuroendocrine Tumor Treatment by Drug Class - Percentage Breakdown of Value Sales for Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Neuroendocrine Tumor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 15-Year Perspective for Neuroendocrine Tumor Treatment by Indication - Percentage Breakdown of Value Sales for Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Neuroendocrine Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Neuroendocrine Tumor Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Neuroendocrine Tumor Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Neuroendocrine Tumor Treatment by Drug Class - Percentage Breakdown of Value Sales for Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Neuroendocrine Tumor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Neuroendocrine Tumor Treatment by Indication - Percentage Breakdown of Value Sales for Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Neuroendocrine Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Neuroendocrine Tumor Treatment by Drug Class - Percentage Breakdown of Value Sales for Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Neuroendocrine Tumor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Australia 15-Year Perspective for Neuroendocrine Tumor Treatment by Indication - Percentage Breakdown of Value Sales for Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications for the Years 2015, 2025 & 2030
• INDIA
  • Neuroendocrine Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 173: India Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Neuroendocrine Tumor Treatment by Drug Class - Percentage Breakdown of Value Sales for Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Neuroendocrine Tumor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 179: India Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: India 15-Year Perspective for Neuroendocrine Tumor Treatment by Indication - Percentage Breakdown of Value Sales for Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Neuroendocrine Tumor Treatment by Drug Class - Percentage Breakdown of Value Sales for Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Neuroendocrine Tumor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: South Korea 15-Year Perspective for Neuroendocrine Tumor Treatment by Indication - Percentage Breakdown of Value Sales for Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Neuroendocrine Tumor Treatment by Drug Class - Percentage Breakdown of Value Sales for Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Neuroendocrine Tumor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Neuroendocrine Tumor Treatment by Indication - Percentage Breakdown of Value Sales for Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Neuroendocrine Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Neuroendocrine Tumor Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Neuroendocrine Tumor Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Neuroendocrine Tumor Treatment by Drug Class - Percentage Breakdown of Value Sales for Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Neuroendocrine Tumor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Neuroendocrine Tumor Treatment by Indication - Percentage Breakdown of Value Sales for Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Neuroendocrine Tumor Treatment by Drug Class - Percentage Breakdown of Value Sales for Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Neuroendocrine Tumor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Argentina 15-Year Perspective for Neuroendocrine Tumor Treatment by Indication - Percentage Breakdown of Value Sales for Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Neuroendocrine Tumor Treatment by Drug Class - Percentage Breakdown of Value Sales for Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Neuroendocrine Tumor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Brazil 15-Year Perspective for Neuroendocrine Tumor Treatment by Indication - Percentage Breakdown of Value Sales for Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Neuroendocrine Tumor Treatment by Drug Class - Percentage Breakdown of Value Sales for Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Neuroendocrine Tumor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Mexico 15-Year Perspective for Neuroendocrine Tumor Treatment by Indication - Percentage Breakdown of Value Sales for Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Neuroendocrine Tumor Treatment by Drug Class - Percentage Breakdown of Value Sales for Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Neuroendocrine Tumor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 15-Year Perspective for Neuroendocrine Tumor Treatment by Indication - Percentage Breakdown of Value Sales for Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Neuroendocrine Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Neuroendocrine Tumor Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Neuroendocrine Tumor Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Neuroendocrine Tumor Treatment by Drug Class - Percentage Breakdown of Value Sales for Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Neuroendocrine Tumor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Neuroendocrine Tumor Treatment by Indication - Percentage Breakdown of Value Sales for Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Neuroendocrine Tumor Treatment by Drug Class - Percentage Breakdown of Value Sales for Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Neuroendocrine Tumor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Iran 15-Year Perspective for Neuroendocrine Tumor Treatment by Indication - Percentage Breakdown of Value Sales for Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Neuroendocrine Tumor Treatment by Drug Class - Percentage Breakdown of Value Sales for Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Neuroendocrine Tumor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Israel 15-Year Perspective for Neuroendocrine Tumor Treatment by Indication - Percentage Breakdown of Value Sales for Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Neuroendocrine Tumor Treatment by Drug Class - Percentage Breakdown of Value Sales for Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Neuroendocrine Tumor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 15-Year Perspective for Neuroendocrine Tumor Treatment by Indication - Percentage Breakdown of Value Sales for Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Neuroendocrine Tumor Treatment by Drug Class - Percentage Breakdown of Value Sales for Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Neuroendocrine Tumor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: UAE 15-Year Perspective for Neuroendocrine Tumor Treatment by Indication - Percentage Breakdown of Value Sales for Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Neuroendocrine Tumor Treatment by Drug Class - Percentage Breakdown of Value Sales for Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Neuroendocrine Tumor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 15-Year Perspective for Neuroendocrine Tumor Treatment by Indication - Percentage Breakdown of Value Sales for Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications for the Years 2015, 2025 & 2030
• AFRICA
  • Neuroendocrine Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Neuroendocrine Tumor Treatment by Drug Class - Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Neuroendocrine Tumor Treatment by Drug Class - Percentage Breakdown of Value Sales for Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Neuroendocrine Tumor Treatment by Distribution Channel - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Neuroendocrine Tumor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Neuroendocrine Tumor Treatment by Indication - Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Africa 15-Year Perspective for Neuroendocrine Tumor Treatment by Indication - Percentage Breakdown of Value Sales for Gastrointestinal NET, Lung NET, Pancreatic NET and Other Indications for the Years 2015, 2025 & 2030

IV. COMPETITION